Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III study of KMW-1 in hospitalized patients with Deep Partial Thickness and Full Thickness thermal burns

Next Previous
X
Search
Trial Profile

Phase III study of KMW-1 in hospitalized patients with Deep Partial Thickness and Full Thickness thermal burns

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bromelains (Primary)
  • Indications Burns
  • Focus Registrational; Therapeutic Use
  • Sponsors Kaken Pharmaceutical

    • Most Recent Events

    • 23 Dec 2022 According to a MediWound media release, The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted NexoBrid marketing authorization for non-surgical eschar removal of deep-partial and full-thickness thermal burns for the adult and pediatric population. NexoBrid is approved under the orphan drug designation granted by the MHLW as a priority review for unmet medical needs.
    • 21 Oct 2021 Primary end point (Percentage of subjects in whom eschar was completely removed) met, according to a Kaken Pharmaceutical media release
    • 21 Oct 2021 According to a Kaken Pharmaceutical media release, results from this trial were presented at the 47th Annual Meeting of the Japanese Society for Burn Injuries

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top